Our 5 research axes
Servier focuses its R&D on 5 therapeutic areas. Within each of them,
the Group has chosen to specialize in a limited number of diseases
where medical needs remain major.
the Group has chosen to specialize in a limited number of diseases
where medical needs remain major.
Diabete
640
million
Type 2 diabetics
will be diagnosed
worldwide in 2040
will be diagnosed
worldwide in 2040
7
th
Cause of death
worldwide
worldwide
3
Programs are designed to promote access
to innovation in the field of diabetes:
DIRECT, IMIDIA and RHAPSODY
to innovation in the field of diabetes:
DIRECT, IMIDIA and RHAPSODY
The number of people with diabetes is expected to rise to 642 million by 2040. Aware that diabetes is the world’s 7th leading cause of death, but also the cause of major health complications, in addition to our vibrant in-house research, we are working in partnership with biotech companies and world-class academic groups to explore novel modes of action.
We also take part in the Innovative Medicines Initiative (IMI), a partnership between the European Commission and the European pharmaceutical industry. In particular, we are involved in three programs to foster innovation—DIRECT, IMIDIA, and RHAPSODY—and better understand why diabetes manifests more progressively in some patients than in others. Ultimately, these programs will help identify the origin and location of the disease, as well as design adapted and personalized therapeutic strategies for homogenous patient groups.